Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease Market Perspective (2018-2029)
2.2 Neurodegenerative Disease Growth Trends by Region
2.2.1 Global Neurodegenerative Disease Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neurodegenerative Disease Historic Market Size by Region (2018-2024)
2.2.3 Neurodegenerative Disease Forecasted Market Size by Region (2024-2029)
2.3 Neurodegenerative Disease Market Dynamics
2.3.1 Neurodegenerative Disease Industry Trends
2.3.2 Neurodegenerative Disease Market Drivers
2.3.3 Neurodegenerative Disease Market Challenges
2.3.4 Neurodegenerative Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Players by Revenue (2018-2024)
3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2018-2024)
3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disease Revenue
3.4 Global Neurodegenerative Disease Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2022
3.5 Neurodegenerative Disease Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disease Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease Breakdown Data by Type
4.1 Global Neurodegenerative Disease Historic Market Size by Type (2018-2024)
4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029)
5 Neurodegenerative Disease Breakdown Data by Application
5.1 Global Neurodegenerative Disease Historic Market Size by Application (2018-2024)
5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Neurodegenerative Disease Market Size (2018-2029)
6.2 North America Neurodegenerative Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Neurodegenerative Disease Market Size by Country (2018-2024)
6.4 North America Neurodegenerative Disease Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Market Size (2018-2029)
7.2 Europe Neurodegenerative Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Neurodegenerative Disease Market Size by Country (2018-2024)
7.4 Europe Neurodegenerative Disease Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Market Size (2018-2029)
8.2 Asia-Pacific Neurodegenerative Disease Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Neurodegenerative Disease Market Size by Region (2018-2024)
8.4 Asia-Pacific Neurodegenerative Disease Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disease Market Size (2018-2029)
9.2 Latin America Neurodegenerative Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Neurodegenerative Disease Market Size by Country (2018-2024)
9.4 Latin America Neurodegenerative Disease Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Market Size (2018-2029)
10.2 Middle East & Africa Neurodegenerative Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Neurodegenerative Disease Market Size by Country (2018-2024)
10.4 Middle East & Africa Neurodegenerative Disease Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurodegenerative Disease Introduction
11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2018-2024)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Disease Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2018-2024)
11.2.5 Pfizer Recent Development
11.3 Merck Serono
11.3.1 Merck Serono Company Detail
11.3.2 Merck Serono Business Overview
11.3.3 Merck Serono Neurodegenerative Disease Introduction
11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2018-2024)
11.3.5 Merck Serono Recent Development
11.4 Biogen Idec
11.4.1 Biogen Idec Company Detail
11.4.2 Biogen Idec Business Overview
11.4.3 Biogen Idec Neurodegenerative Disease Introduction
11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2018-2024)
11.4.5 Biogen Idec Recent Development
11.5 TEVA
11.5.1 TEVA Company Detail
11.5.2 TEVA Business Overview
11.5.3 TEVA Neurodegenerative Disease Introduction
11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2018-2024)
11.5.5 TEVA Recent Development
11.6 UCB
11.6.1 UCB Company Detail
11.6.2 UCB Business Overview
11.6.3 UCB Neurodegenerative Disease Introduction
11.6.4 UCB Revenue in Neurodegenerative Disease Business (2018-2024)
11.6.5 UCB Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Detail
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction
11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2018-2024)
11.7.5 Boehringer Ingelheim Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neurodegenerative Disease Introduction
11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2018-2024)
11.8.5 Sanofi Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Detail
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction
11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2018-2024)
11.9.5 GlaxoSmithKline Recent Development
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Detail
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Introduction
11.10.4 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.10.5 Livzon Pharmaceutical Recent Development
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Detail
11.11.2 Haisco Pharmaceutical Business Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Introduction
11.11.4 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.11.5 Haisco Pharmaceutical Recent Development
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Detail
11.12.2 Jingxin Pharmaceutical Business Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Introduction
11.12.4 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.12.5 Jingxin Pharmaceutical Recent Development
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Detail
11.13.2 Dongcheng Biochemicals Business Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Introduction
11.13.4 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2018-2024)
11.13.5 Dongcheng Biochemicals Recent Development
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Detail
11.14.2 Hisun Pharmaceutical Business Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Introduction
11.14.4 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.14.5 Hisun Pharmaceutical Recent Development
11.15 Luye Pharma
11.15.1 Luye Pharma Company Detail
11.15.2 Luye Pharma Business Overview
11.15.3 Luye Pharma Neurodegenerative Disease Introduction
11.15.4 Luye Pharma Revenue in Neurodegenerative Disease Business (2018-2024)
11.15.5 Luye Pharma Recent Development
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Detail
11.16.2 Ark Pharmaceutical Business Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Disease Introduction
11.16.4 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.16.5 Ark Pharmaceutical Recent Development
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Detail
11.17.2 Kanghong Pharmaceutical Business Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Introduction
11.17.4 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.17.5 Kanghong Pharmaceutical Recent Development
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Detail
11.18.2 Huahai Pharmaceutical Business Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Introduction
11.18.4 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.18.5 Huahai Pharmaceutical Recent Development
11.19 BORA PHARMACEUTICALS
11.19.1 BORA PHARMACEUTICALS Company Detail
11.19.2 BORA PHARMACEUTICALS Business Overview
11.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Introduction
11.19.4 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2018-2024)
11.19.5 BORA PHARMACEUTICALS Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of NMDA
Table 3. Key Players of SSRIs
Table 4. Key Players of Dopamine Inhibitors
Table 5. Global Neurodegenerative Disease Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Neurodegenerative Disease Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Neurodegenerative Disease Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Neurodegenerative Disease Market Share by Region (2018-2024)
Table 9. Global Neurodegenerative Disease Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Neurodegenerative Disease Market Share by Region (2024-2029)
Table 11. Neurodegenerative Disease Market Trends
Table 12. Neurodegenerative Disease Market Drivers
Table 13. Neurodegenerative Disease Market Challenges
Table 14. Neurodegenerative Disease Market Restraints
Table 15. Global Neurodegenerative Disease Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Neurodegenerative Disease Market Share by Players (2018-2024)
Table 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Table 18. Ranking of Global Top Neurodegenerative Disease Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2018-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neurodegenerative Disease Product Solution and Service
Table 22. Date of Enter into Neurodegenerative Disease Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2018-2024)
Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2024-2029)
Table 28. Global Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Neurodegenerative Disease Revenue Market Share by Application (2018-2024)
Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Neurodegenerative Disease Revenue Market Share by Application (2024-2029)
Table 32. North America Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 34. North America Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 37. Europe Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Neurodegenerative Disease Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Neurodegenerative Disease Market Size by Region (2018-2024) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Disease Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 43. Latin America Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Neurodegenerative Disease Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 47. Novartis Company Detail
Table 48. Novartis Business Overview
Table 49. Novartis Neurodegenerative Disease Product
Table 50. Novartis Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 51. Novartis Recent Development
Table 52. Pfizer Company Detail
Table 53. Pfizer Business Overview
Table 54. Pfizer Neurodegenerative Disease Product
Table 55. Pfizer Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 56. Pfizer Recent Development
Table 57. Merck Serono Company Detail
Table 58. Merck Serono Business Overview
Table 59. Merck Serono Neurodegenerative Disease Product
Table 60. Merck Serono Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 61. Merck Serono Recent Development
Table 62. Biogen Idec Company Detail
Table 63. Biogen Idec Business Overview
Table 64. Biogen Idec Neurodegenerative Disease Product
Table 65. Biogen Idec Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 66. Biogen Idec Recent Development
Table 67. TEVA Company Detail
Table 68. TEVA Business Overview
Table 69. TEVA Neurodegenerative Disease Product
Table 70. TEVA Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 71. TEVA Recent Development
Table 72. UCB Company Detail
Table 73. UCB Business Overview
Table 74. UCB Neurodegenerative Disease Product
Table 75. UCB Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 76. UCB Recent Development
Table 77. Boehringer Ingelheim Company Detail
Table 78. Boehringer Ingelheim Business Overview
Table 79. Boehringer Ingelheim Neurodegenerative Disease Product
Table 80. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 81. Boehringer Ingelheim Recent Development
Table 82. Sanofi Company Detail
Table 83. Sanofi Business Overview
Table 84. Sanofi Neurodegenerative Disease Product
Table 85. Sanofi Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 86. Sanofi Recent Development
Table 87. GlaxoSmithKline Company Detail
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Neurodegenerative Disease Product
Table 90. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 91. GlaxoSmithKline Recent Development
Table 92. Livzon Pharmaceutical Company Detail
Table 93. Livzon Pharmaceutical Business Overview
Table 94. Livzon Pharmaceutical Neurodegenerative Disease Product
Table 95. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 96. Livzon Pharmaceutical Recent Development
Table 97. Haisco Pharmaceutical Company Detail
Table 98. Haisco Pharmaceutical Business Overview
Table 99. Haisco Pharmaceutical Neurodegenerative Disease Product
Table 100. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 101. Haisco Pharmaceutical Recent Development
Table 102. Jingxin Pharmaceutical Company Detail
Table 103. Jingxin Pharmaceutical Business Overview
Table 104. Jingxin Pharmaceutical Neurodegenerative Disease Product
Table 105. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 106. Jingxin Pharmaceutical Recent Development
Table 107. Dongcheng Biochemicals Company Detail
Table 108. Dongcheng Biochemicals Business Overview
Table 109. Dongcheng Biochemicals Neurodegenerative Disease Product
Table 110. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 111. Dongcheng Biochemicals Recent Development
Table 112. Hisun Pharmaceutical Company Detail
Table 113. Hisun Pharmaceutical Business Overview
Table 114. Hisun Pharmaceutical Neurodegenerative Disease Product
Table 115. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 116. Hisun Pharmaceutical Recent Development
Table 117. Luye Pharma Company Detail
Table 118. Luye Pharma Business Overview
Table 119. Luye Pharma Neurodegenerative Disease Product
Table 120. Luye Pharma Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 121. Luye Pharma Recent Development
Table 122. Ark Pharmaceutical Company Detail
Table 123. Ark Pharmaceutical Business Overview
Table 124. Ark Pharmaceutical Neurodegenerative Disease Product
Table 125. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 126. Ark Pharmaceutical Recent Development
Table 127. Kanghong Pharmaceutical Company Detail
Table 128. Kanghong Pharmaceutical Business Overview
Table 129. Kanghong Pharmaceutical Neurodegenerative Disease Product
Table 130. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 131. Kanghong Pharmaceutical Recent Development
Table 132. Huahai Pharmaceutical Company Detail
Table 133. Huahai Pharmaceutical Business Overview
Table 134. Huahai Pharmaceutical Neurodegenerative Disease Product
Table 135. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 136. Huahai Pharmaceutical Recent Development
Table 137. BORA PHARMACEUTICALS Company Detail
Table 138. BORA PHARMACEUTICALS Business Overview
Table 139. BORA PHARMACEUTICALS Neurodegenerative Disease Product
Table 140. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 141. BORA PHARMACEUTICALS Recent Development
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disease Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Neurodegenerative Disease Market Share by Type: 2022 VS 2029
Figure 3. NMDA Features
Figure 4. SSRIs Features
Figure 5. Dopamine Inhibitors Features
Figure 6. Global Neurodegenerative Disease Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 7. Global Neurodegenerative Disease Market Share by Application: 2022 VS 2029
Figure 8. Parkinson’s Disease Case Studies
Figure 9. Huntington Disease Case Studies
Figure 10. Amyotrophic Lateral Sclerosis Case Studies
Figure 11. Alzheimer’s Disease Case Studies
Figure 12. Neurodegenerative Disease Report Years Considered
Figure 13. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Neurodegenerative Disease Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Neurodegenerative Disease Market Share by Region: 2022 VS 2029
Figure 16. Global Neurodegenerative Disease Market Share by Players in 2022
Figure 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2022
Figure 19. North America Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 21. United States Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 25. Germany Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Neurodegenerative Disease Market Share by Region (2018-2029)
Figure 33. China Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 41. Mexico Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 45. Turkey Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 48. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 49. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 50. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 51. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 52. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 54. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 56. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 57. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 58. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 59. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 60. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 61. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 62. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 63. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 64. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 65. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed